CN Patent

CN104906582A — 包含sglt2抑制剂、dpp-iv抑制剂和任选的另一种抗糖尿病药的药物组合物及其用途

Assigned to Boehringer Ingelheim International GmbH · Expires 2015-09-16 · 11y expired

What this patent protects

本发明涉及权利要求1的包含SGLT2抑制剂、DPPIV抑制剂和第三种抗糖尿病药的药物组合物，其适于治疗或预防一种或多种选自I型糖尿病、II型糖尿病、葡萄糖耐量降低和高血糖症的病症。此外，本发明涉及一种预防或治疗代谢障碍及相关病症的方法。

USPTO Abstract

本发明涉及权利要求1的包含SGLT2抑制剂、DPPIV抑制剂和第三种抗糖尿病药的药物组合物，其适于治疗或预防一种或多种选自I型糖尿病、II型糖尿病、葡萄糖耐量降低和高血糖症的病症。此外，本发明涉及一种预防或治疗代谢障碍及相关病症的方法。

Drugs covered by this patent

Patent Metadata

Patent number
CN104906582A
Jurisdiction
CN
Classification
—
Expires
2015-09-16
Drug substance claim
No
Drug product claim
No
Assignee
Boehringer Ingelheim International GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.